ReachMD XM 157 Announces Medical Information Feature on Treatment Options for Management of Hy...( CHICAGO Oct. 27 /- ReachMD XM 157...),Health

CHICAGO, Oct. 27 /PRNewswire/ -- ReachMD XM 157 announces a new "Medical Industry Feature of the Week" highlighting a vasopressin receptor antagonist and its effects on management of euvolemic and hypervolemic hyponatremia in the hospital setting.

ReachMD XM 157, the first and only network for medical professionals, will air the program "AVP Antagonists: Turning the Tide Against Hyponatremia" four times a day October 27-31, November 10-14, and January 5-8. Healthcare professionals can tune in to XM Satellite Radio Channel 157 or listen OnDemand at http://www.ReachMD.com/AVP1. Use promo code VaprisolPR to listen and to receive a free 6-month membership to ReachMD.com.

The program features interviews with Joseph Verbalis, MD, Professor of Medicine and Physiology at Georgetown University Medical Center and Scott Beegle, MD, Assistant Professor of Medicine at Albany Medical College. Program host Lee Freedman, MD, Internal Medicine, Northwestern Memorial Hospital, Evanston Northwestern Healthcare: Evanston Hospital, Highland Park Hospital, and Glenbrook Hospital will interview Dr. Verbalis and Dr. Beegle. The topics include:

-- Hyponatremia incidence, causes, and consequences

-- Diagnostic algorithm and general treatment principles

-- AVP antagonists rationale for treatment

-- VAPRISOL(R) efficacy, safety and dosing information

"AVP Antagonists: Turning the Tide Against Hyponatremia" is sponsored by Astellas Pharma US, Inc. in support of VAPRISOL(R) (conivaptan hydrochloride injection), a nonpeptide dual AVP antagonist indicated for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.

Gary Epstein, CEO of ReachMD said, "We're excited to work with Astellas to broadcast this very special program. Our programming continues to diversify which helps all types of physicians gain the latest information about disorders and new a
'/>"/>